This work demonstrated the utility of the synthetic PEG12-KL4 peptide to deliver siRNAs targeting both EGFR and PD-L1 simultaneously as a potential therapeutic strategy against NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.